Stocks Health care IKT
NASDAQ · Health careInhibikase Therapeutics, Inc. (IKT)
It posted a net loss of $60.6M. In fiscal 2025 capital spending exceeded operating cash flow by $27.8M. At June 30, 2026 it held $31.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
Key facts about Inhibikase Therapeutics, Inc.
- Net worth
- Inhibikase Therapeutics, Inc. has a market value (market cap) of $216.3M at the latest share price, and shareholders' equity of $153.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2024 revenue was $0 (-100.0% year on year), with a net loss of $27.5M.
- Cash flow
- In fiscal 2025 operations used $27.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 11, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Inhibikase Therapeutics, Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Inhibikase Therapeutics, Inc. does
Inhibikase Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker IKT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$48.3M | -$0.49 | -$27.8M |
| 2024 | $0 | -$27.5M | -$1.16 | -$19.1M |
| 2023 | $260.5K | -$19M | -$3.16 | -$18.1M |
| 2022 | $123.4K | -$18.1M | -$3.79 | -$17.6M |
| 2021 | $3.1M | -$14.8M | -$4.26 | -$14.3M |
| 2021 | $698.5K | -$2.8M | -$1.84 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Inhibikase Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 20, 2026
- September 8, 2026
- August 26, 2026Auditor change 8-K
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 11, 2026
- August 11, 2026
- August 11, 2026
- July 31, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running Inhibikase Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| July 30, 2026 | Berman Dennis NDirector | Exercised options | 21,854 | $27.5K |
| July 29, 2026 | Ra Capital Management, L.P.10% owner | Other changeindirect | 18,030,000 | - |
| February 21, 2026 | Munshi AmitDirector | Other change | 19,089 | - |
| February 21, 2026 | Cabell ChristopherPresident & Head of R&D | Other change | 338,282 | - |
| February 21, 2026 | Aurentz VincentDirector | Other change | 255,299 | - |
| November 21, 2025 | Sands Capital Life Sciences Pulse Fund II, L.P.10% owner | Bought | 2,068,965 | $3M |
Who owns IKT
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| ADAR1 Capital Management, LLC13G, passive with 2 related filers | 9.9% | May 15, 2026 |
| Commodore Capital LP13G, passive with 3 related filers | 9.9% | May 15, 2026 |
| Fairmount Funds Management LLC13G, passive with 3 related filers | 9.9% | February 17, 2026 |
| RA Capital Management, L.P.13G, passive with 3 related filers | 9.9% | July 31, 2026 |
| Sands Capital Life Sciences Pulse Fund II, L.P.13G, passive with 2 related filers | 9.3% | August 13, 2026 |
| Perceptive Advisors LLC13G, passive with 2 related filers | 6.9% | August 14, 2026 |
| Trails Edge Capital Partners, LP13G, passive with 2 related filers | 6.1% | May 15, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 106 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Sands Capital Alternatives, LLC | 13,018,965 | 0 |
| Soleus Capital Management, L.P. | 10,875,000 | 0 |
| Trails Edge Capital Partners, LP | 9,051,318 | +993,973 |
| Fairmount Funds Management LLC | 8,625,000 | 0 |
| BlackRock, Inc. | 7,768,057 | +1,464,624 |
| Kalehua Capital Management LLC | 7,643,780 | +1,149,282 |
| ADAR1 Capital Management, LLC | 7,387,205 | +780,633 |
| Blackstone Inc. | 5,938,276 | 0 |
| Siren, L.L.C. | 5,850,000 | 0 |
| Nantahala Capital Management, LLC | 5,403,726 | +2,701,863 |
| Commodore Capital LP | 5,397,488 | 0 |
| Vanguard Capital Management LLC | 4,935,354 | +484,689 |
| Millennium Management LLC | 4,028,102 | +1,100,025 |
| Saturn V Capital Management LP | 3,869,056 | +5,611 |
| Spruce Street Capital LP | 3,581,603 | 0 |
| Squadron Capital Management LLC | 3,000,000 | -500,000 |
| Geode Capital Management, LLC | 2,607,129 | +436,943 |
| State Street Corp | 1,909,101 | +223,285 |
| SummitTX Capital, L.P. | 1,780,262 | +255,726 |
| Integral Health Asset Management, LLC | 1,350,000 | 0 |
Insiders
6 insiders reported holding 21,236,155 shares in total, about $32.9M at the last price.
| Holder | Shares |
|---|---|
| Sands Capital Life Sciences Pulse Fund II, L.P.10% owner | 13,018,965 |
| Ra Capital Management, L.P.10% owner | 6,970,0006,970,000 held indirectly |
| Cabell ChristopherPresident & Head of R&D | 676,564 |
| Aurentz VincentDirector | 510,596 |
| Munshi AmitDirector | 38,176 |
| Berman Dennis NDirector | 21,854 |
Questions about IKT
What does Inhibikase Therapeutics, Inc. do?
Inhibikase Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as IKT. Its shares trade on NASDAQ under the ticker IKT.
What is Inhibikase Therapeutics, Inc.'s net worth?
Inhibikase Therapeutics, Inc. has a market value (market cap) of $216.3M at the latest share price, and shareholders' equity of $153.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Inhibikase Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $60.6M.
When did Inhibikase Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from October 21, 2026.
When is Inhibikase Therapeutics, Inc.'s next earnings report?
Inhibikase Therapeutics, Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare IKT with
Follow IKT
Get an email when Inhibikase Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Inhibikase Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.